Literature DB >> 6350731

Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients.

A Hagenbeek, W Sizoo, B Löwenberg.   

Abstract

The effect of low-dose cytosine arabinoside (10 mg/m2 q 12 h for 21 days) was evaluated in four patients with acute myelocytic leukemia. Neither were significant changes in the percentage of leukemic cells in the bone marrow noted, nor were there any signs of a percentual increase of differentiated cells. The total observation time was 60 days. In the blood the absolute number of leukemic cells showed a significant increase. In conclusion, no complete or partial remissions were achieved.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6350731     DOI： 10.1016/0145-2126(83)90109-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  4 in total

1.  In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.

Authors:  C S Chan; G P Schechter
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia.

Authors:  U Jehn; R De Bock; C Haanen
Journal:  Blut       Date:  1984-05

3.  Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Authors:  H J Weh; R Zschaber; D K Hossfeld
Journal:  Blut       Date:  1984-04

4.  Low-dose Ara-C in the treatment of acute leukemia. Cytotoxicity or differentiation induction?

Authors:  D Hoelzer; A Ganser; B Anger; E Seifried; H Heimpel
Journal:  Blut       Date:  1984-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.